儿童血液系统恶性肿瘤合并急性呼吸衰竭的一线呼吸支持
该回顾性队列分析基于2010年1月1日至2019年12月31日北美113个PICU的VPS数据,纳入2480例0-21岁血液系统恶性肿瘤因急性呼吸衰竭需呼吸支持的患儿,共3013次住院。仅无创通气组从2010年9.6%升至2019年43.1%,仅有创通气组从80.1%降至34.2%(p<0.001)。无创通气失败组死亡率最高(36.6% vs 仅无创8.1% vs 仅有创30.5%,p<0.001),但仅有创组死亡风险最高(中位PRISM III ROM 8.1% vs 2.8% vs 5.5%,p<0.001),无创失败组中位PICU住院最长(15.2 d vs 6.1 d和9.0 d,p<0.001)。年龄较大与无创通气失败风险降低相关,非霍奇金淋巴瘤较急性淋巴细胞白血病与失败风险增加相关。
要点
- 2010至2019年儿童血液肿瘤合并急性呼吸衰竭中仅无创通气比例从9.6%升至43.1%,仅有创通气从80.1%降至34.2%(p<0.001)。
- 无创通气失败后转为有创通气者死亡率最高:36.6%,仅无创通气8.1%,仅有创通气30.5%(p<0.001)。
- 仅有创通气组死亡风险最高:中位PRISM III ROM 8.1%,仅无创2.8%,无创失败5.5%(p<0.001)。
- 无创通气失败组中位PICU住院时间最长:15.2 d,仅无创6.1 d,仅有创9.0 d(p<0.001)。
- 年龄较大与无创通气失败风险降低相关,非霍奇金淋巴瘤较急性淋巴细胞白血病与无创通气失败风险增加相关。
适用人群与场景
- 0-21岁血液系统恶性肿瘤患儿,因急性呼吸衰竭入住参与VPS的北美PICU并需要呼吸支持。
- 数据来源为2010年1月1日至2019年12月31日113个北美PICU的VPS记录,共2480例患儿、3013次住院。
研究设计与关键结果
- 研究类型为回顾性队列分析,使用虚拟儿科系统(VPS,LLC)2010年1月1日至2019年12月31日数据,纳入113个北美PICU的2480例0-21岁血液系统恶性肿瘤合并急性呼吸衰竭需呼吸支持患儿,共3013次住院。
- 3013次住院中,868次(28.8%)仅接受一线无创通气,1544次(51.2%)仅接受一线有创通气,601次(19.9%)无创通气失败后需要有创通气。
- 2010年至2019年,仅无创通气组从9.6%增至43.1%,仅有创通气组从80.1%降至34.2%(p<0.001)。
- 无创通气失败组死亡率最高,与仅无创通气组和仅有创通气组比较分别为36.6% vs 8.1% vs 30.5%(p<0.001)。
- 死亡风险(ROM)在仅有创通气组最高,与仅无创通气组和无创失败组比较中位PRISM III ROM分别为8.1% vs 2.8% vs 5.5%(p<0.001)。
- 无创通气失败组中位PICU住院时间最长,与其他两组比较分别为15.2 d vs 6.1 d和9.0 d(p<0.001)。
- 年龄较大与无创通气失败风险降低显著相关,非霍奇金淋巴瘤诊断较急性淋巴细胞白血病与无创通气失败风险增加显著相关。
证据类型、等级与局限
- 证据类型:回顾性队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于PICU中血液系统恶性肿瘤合并急性呼吸衰竭的患儿,无创通气已取代有创通气成为最常见的初始呼吸支持方式。
- 无创通气失败率仍高,且失败后转为有创通气者观察死亡率高,尽管其PICU入院时死亡风险较低。
- 年龄较大与无创通气失败风险降低相关,非霍奇金淋巴瘤较急性淋巴细胞白血病与无创通气失败风险增加相关,可提示临床关注无创通气失败风险较高的人群。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To characterize trends in noninvasive ventilation (NIV) and invasive mechanical ventilation (IMV) use over time in children with hematologic malignancy admitted to the PICU with acute respiratory failure (ARF), and to identify risk factors associated with NIV failure requiring transition to IMV.
DESIGN: Retrospective cohort analysis using the Virtual Pediatric Systems (VPS, LLC) between January 1, 2010 and December 31, 2019.
SETTING: One hundred thirteen North American PICUs participating in VPS.
PATIENTS: Two thousand four hundred eighty children 0-21 years old with hematologic malignancy admitted to participating PICUs for ARF requiring respiratory support.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: There were 3013 total encounters, of which 868 (28.8%) received first-line NIV alone (NIV only), 1544 (51.2%) received first-line IMV (IMV only), and 601 (19.9%) required IMV after a failed NIV trial (NIV failure). From 2010 to 2019, the NIV only group increased from 9.6% to 43.1% and the IMV only group decreased from 80.1% to 34.2% (p < 0.001). The NIV failure group had the highest mortality compared with NIV only and IMV only (36.6% vs. 8.1%, vs. 30.5%, p < 0.001). However, risk-of-mortality (ROM) was highest in the IMV only group compared with NIV only and NIV failure (median Pediatric Risk of Mortality III ROM 8.1% vs. 2.8% vs. 5.5%, p < 0.001). NIV failure patients also had the longest median PICU length of stay compared with the other two study groups (15.2 d vs. 6.1 and 9.0 d, p < 0.001). Higher age was associated with significantly decreased odds of NIV failure, and diagnosis of non-Hodgkin lymphoma was associated with significantly increased odds of NIV failure compared with acute lymphoid leukemia.
CONCLUSIONS: For children with hematologic malignancy admitted to the PICU with ARF, NIV has replaced IMV as the most common initial therapy. NIV failure rate remains high with high-observed mortality despite lower PICU admission ROM.
参考来源
- Asif H, McNeer JL, Ghanayem NS, et al. First-Line Respiratory Support for Children With Hematologic Malignancy and Acute Respiratory Failure. Crit Care Explor. 2024. PMID: 38601458. doi:10.1097/CCE.0000000000001076
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。